DHSPB7 ve tetranektin düzeyleri COVID-19’un şiddeti ile ilişkilidir

Abstract

Amaç: COVID-19'un kardiyovasküler sistem üzerinde akut ve kronik olumsuz etkileri olabilmektedir. Isı şoku proteini beta-7 (HSPB7), kardiyovasküler bir ısı şoku proteinidir ve tetranektin, tip-C kalsiyum (Ca) bağlayıcı bir lektindir. Bu çalışmanın amacı, COVID-19'da HSPB7, tetranektin, hastalık şiddeti ve miyokardiyal hasar arasındaki ilişkiyi tespit etmektir. Gereç ve yöntem: Bu çalışmaya 26 COVID-19 hastası ve 26 yaşı ile cinsiyeti eşleştirilmiş sağlıklı kontrol dahil edildi. Demografik özellikler, rutin hemogramlar ve biyokimyasal parametreler kaydedildi. COVID-19 hastalarının klinik ve laboratuvar verileri kullanılarak hafif, orta ve şiddetli COVID-19 hastası olarak sınıflandırıldı. HSPB7 ve tetranektin seviyeleri ticari ELISA kitleri kullanılarak ölçüldü. Bulgular: COVID-19 hastalarında C-reaktif protein, açlık glukozu, ferritin, nötrofil-lenfosit, monosit-lenfosit ve trombosit-lenfosit oranları anlamlı olarak artarken, kalsiyum ve albümin ise azaldı (p<0,05). Şiddetli COVID-19 hastalarında solunum sayısı, D-dimer ve ferritin daha yüksekken, SO2 ve lenfosit sayıları daha düşüktü (p<0,05). Serum HSPB7 düzeyleri COVID-19 hastalarında sağlıklı kontrollere göre daha yüksekti (p<0,01), tetranektin düzeyi ise daha düşüktü (p<0,001). Hastalığın şiddetine göre değerlendirildiğinde, HSPB7 düzeyinin şiddetli COVID-19 hastalarında arttığı, tetranektin düzeyinin ise hastalığın şiddetine paralel olarak azaldığı görüldü (sırasıyla p<0,001 ve p<0,001). HSPB7 konsantrasyonunun ferritin ile pozitif korelasyon gösterdiği görüldü (p=0,002). Tetranektin, HSPB7, ferritin ve troponin ile negatif korelasyon gösterdi (sırasıyla p=0,041, p<0,01 ve p=0,005). Sonuç: Mevcut çalışmanın sonuçları, tetranektini COVID-19 hastalarında, kardiyak hasarın ciddiyetinin belirlenmesinde ve daha kapsamlı bir şekilde anlaşılması için potansiyel bir biyobelirteç olabileceğini göstermektedir.

Keywords

• COVID-19
• HSPB7
• tetranektin
• kardiyak hasar

HSPB7 and tetranectin levels are associated with severity of COVID-19

Abstract

Purpose: COVID-19 may have acute and chronic adverse effects on the cardiovascular system. Heat shock protein beta-7 (HSPB7) is a cardiovascular heat-shock protein, and tetranectin is a type-C calcium (Ca)-binding lectin. The present study was conducted to investigate the relationship between HSPB7, tetranectin, disease severity and myocardial injury in COVID-19. Materials and methods: This study included 26 COVID-19 patients and 26 age and sex-matched healthy controls. Demographic characteristics, routine hemograms, and biochemical parameters were recorded. COVID-19 patients were classified as having mild to moderate and severe COVID-19 using clinical and laboratory data. HSPB7 and tetranectin levels were measured using commercial ELISA kits. Results: C-reactive protein, fasting glucose, ferritin, neutrophil-to-lymphocyte, monocyte-to-lymphocyte, and platelet-to-lymphocyte ratios were significantly elevated, whereas calcium, and albumin were decreased in COVID-19 patients (p<0.05). Respiratory rate, D-dimer, and ferritin were higher while SO2 and lymphocyte counts were lower in severe COVID-19 patients (p<0.05). Serum HSPB7 levels were higher in COVID-19 patients vs healthy controls (p<0.01), whereas tetranectin concentration was lower (p<0.001). When the cases were evaluated according to the severity of the disease it was observed that, HSPB7 level was increased in patients with severe COVID-19 and tetranectin was decreased parallel to the severity of the disease (p<0.001 and p<0.001, respectively). HSPB7 concentration was positively correlated with ferritin (p=0.002). Tetranectin was negatively correlated with HSPB7, ferritin and troponin (p=0.041, p<0.01, and p=0.005, respectively). Conclusion: The consequence of the present study indicates tetranectin as a potential biomarker for an accurate and more comprehensive understanding severity of cardiac damage in COVID-19 patients.

Keywords

• COVID-19
• HSPB7
• tetranectin
• cardiac injury

References

1. Petersen E, Koopmans M, Go U, Hamer DH, et al. SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238-e244. doi:10.1016/s1473-3099(20)30484-9
2. Gates B. Responding to covid-19 — a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677-1679. doi:10.1056/nejmp2003762
3. Guo T, Fan Y, Chen M, et al. Cardiovascular ımplications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017
4. Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones. 2009;14(1):105-111. doi:10.1007/s12192-008-0068-7
5. Wu T, Mu Y, Bogomolovas J, et al. HSPB7 is indispensable for heart development by modulating actin filament assembly. Proc Natl Acad Sci USA. 2017;114(45):11956-11961. doi:10.1073/pnas.1713763114
6. Chiu TF, Li CH, Chen CC, et al. Association of plasma concentration of small heat shock protein B7 with acute coronary syndrome. Circ J. 2013;76(9):2226-2233. doi:10.1253/circj.cj-12-0238
7. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL. Tetranectin binds to the kringle 1-4 form of angiostatin and modifies its functional activity. J Biomed Biotechnol. 2004;2004(2):73-78. doi:10.1155/s1110724304307096
8. Yin X, Subramanian S, Hwang SJ, et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol. 2014;34(4):939-945. doi:10.1161/ATVBAHA.113.30291

9. Chen Y, Han H, Yan X, et al. Tetranectin as a potential biomarker for stable coronary artery disease. Sci Rep. 2015;5:1-8. doi:10.1038/srep17632
10. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5
11. Moutchia J, Pokharel P, Kerri A, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One. 2020;15(10):1-25. doi:10.1371/journal.pone.0239802
12. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85-164. doi:10.1016/B978-0-12-385885-6.00009-2
13. Djordjevic D, Rondovic G, Surbatovic M, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically Ill and Injured patients: Which ratio to choose to predict outcome and nature of bacte. Mediators Inflamm. 2018:3758068. doi:10.1155%2F2018%2F3758068
14. Karimi A, Shobeiri P, Kulasinghe A, Rezaei N. Novel systemic ınflammation markers to predict COVID-19 prognosis. Front Immunol. 2021;12:741061. doi:10.3389/fimmu.2021.741061
15. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The role of hematological ındices in patients with acute coronary syndrome. Dis Markers. 2017;2017:3041565. doi:10.1155/2017/3041565
16. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-1208. doi:10.1007/s00277-020-04019-0
17. Naess A, Nilssen SS, Mo R, Eide GE, Sjursen H. Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever. Infection. 2017;45(3):299-307. doi:10.1007/s15010-016-0972-1
18. Silvin A, Chapuis N, Dunsmore G, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182(6):1401-1418. doi:10.1016/j.cell.2020.08.002
19. Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol. 2020;42:11-18.
20. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. doi:10.1111/j.1365-2249.2004.02415.x
21. Li L, Zhou Q, Xu J. Changes of laboratory cardiac markers and mechanisms of cardiac ınjury in coronavirus disease 2019. Biomed Res Int. 2020;7413673. doi:10.1155%2F2020%2F7413673
22. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. Chin Med J (Engl). 2020;133(11):1261-1267. doi:10.1097/cm9.0000000000000824
23. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8(5):518-526. doi:10.1016/S2213-2600(20)30121-1
24. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/s0140-6736(20)30566-3
26. Xiong Y, Sun D, Liu Y, et al. Clinical and high-resolution CT features of the COVID-19 infection: Comparison of the initial and follow-up changes. Invest Radiol. 2020;55(6):332-339. doi:10.1097/rli.0000000000000674
27. Krief S, Faivre JF, Robert P. Identification and characterization of cvHsp. A novel human small stress protein selectively expressed in cardiovascular and insulin-sensitive tissues. J Biol Chem. 1999;274(51):36592-36600. doi:10.1074/jbc.274.51.36592
28. Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. FEBS J. 2005;272(11):2613-2627. doi:10.1111/j.1742-4658.2005.04708.x
29. Rüdebusch J, Benkner A, Poesch A, et al. Dynamic adaptation of myocardial proteome during heart failure development. PLoS One. 2017;12(10):1-13. doi:10.1371%2Fjournal.pone.0185915
30. McDonald K, Glezeva N, Collier P, et al. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci Rep. 2020;10(1):7507. doi:10.1038%2Fs41598-020-64558-4
31. Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070-2079. doi:10.1093/eurheartj/ehaa408
32. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. doi:10.1001/jamacardio.2020.0950
33. Babapoor Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723.
34. Li Y, Hu Y, Yu J, et al. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Investig. 2020;100(6):794-800. doi:10.1038%2Fs41374-020-0431-6
35. Giamarellos Bourboulis EJ, Netea MG, Rovina N, et al. Complex ımmune dysregulation in COVID-19 patients with severe respiratory failure clinical and translational report complex ımmune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000. doi:10.1016/j.chom.2020.04.009
36. Basu Ray I, Almaddah NK, Vaqar S, Soos MP. Cardiac Manifestations of Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 12, 2024.
37. Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, Goldman M. Takotsubo cardiomyopathy in COVID-19. J Am Coll Cardiol. 2020;76(5):628-629. doi:10.1016/j.jacc.2020.05.068
38. Tobler DL, Pruzansky AJ, Naderi S, Ambrosy AP, Slade JJ. Long-term cardiovascular effects of COVID-19: Emerging data relevant to the cardiovascular clinician. Curr Atheroscler Rep. 2022;24(7):563-570. doi:10.1007/s11883-022-01032-8